Fmr LLC Sells 1,166,748 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

FMR LLC reduced its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 19.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,857,668 shares of the biopharmaceutical company's stock after selling 1,166,748 shares during the period. FMR LLC owned 7.32% of Celldex Therapeutics worth $122,753,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of CLDX. EverSource Wealth Advisors LLC raised its position in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 878 shares during the period. Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $81,000. KBC Group NV grew its position in Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock valued at $94,000 after acquiring an additional 1,647 shares during the period. AlphaQuest LLC lifted its holdings in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 2,705 shares during the last quarter. Finally, Aristides Capital LLC bought a new position in Celldex Therapeutics in the 4th quarter valued at $202,000.

Celldex Therapeutics Trading Up 2.8 %

Shares of Celldex Therapeutics stock traded up $0.50 during trading on Friday, hitting $18.30. 457,867 shares of the stock were exchanged, compared to its average volume of 882,232. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -7.12 and a beta of 1.59. The company has a fifty day moving average price of $19.54 and a 200-day moving average price of $23.92.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. UBS Group initiated coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 target price on the stock. Finally, The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Celldex Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.